This week in health care trends, our spotlight on oncology clinical pathways and utilization management includes updates about a new pathways collaboration, breast cancer therapy adherence, and the future of clinical pathways.
This week in healthcare, 360,000 Americans may see their Obamacare premiums rise if they don’t submit proof of income.
This week in healthcare, UnitedHealth announces its entry into 20 new state exchange marketplaces and a study measures the value of specialty drugs in breast cancer, RA, and MS.
This week in healthcare, Sandoz became the first manufacturer to register a biosimilar under the new FOB pathway and a new report shows states struggling to meet even half the American Cancer Society’s benchmarks for cancer treatment and prevention. Filgrastim Marks First Official U.S. Biosimilar Filed Under Pathway [login required] Late last month, Sandoz became […]
Express Scripts excludes higher-cost cancer supportive care & anemia drugs from formulary; FDA will issue guidance on approval for cancer diagnostics.
This week in healthcare, the FDA releases a guide on biosimilars and at Mayo Clinic measles put cancer into “complete remission”.
The Affordable Care Act (ACA) contains a number of controversial provisions that are going to change the healthcare marketplace. The creation of a pathway that allows the FDA to approve generic forms of biologics has the potential to be one of the most impactful provisions in the ACA. Since the passage of the ACA the […]
How does the impact of specialty pharmacy management trickle down to affect patient access to new product innovation?
Could implementing “option pricing” in the healthcare realm reduce downside risk and encourage greater flexibility into shared savings contracts, like ACOs?